Singapore markets open in 43 minutes

Straits Times Index
3,330.09
+11.64(+0.35%)
S&P 500
5,306.04
+1.32(+0.02%)
Dow
38,852.86
-216.74(-0.55%)
Nasdaq
17,019.88
+99.08(+0.59%)
Bitcoin USD
68,295.25
-1,047.88(-1.51%)
CMC Crypto 200
1,481.30
-15.16(-1.01%)

MRK Jul 2024 140.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.2000

-0.1000

(-33.33%)

As of 02:05PM EDT. Market open.

Business Wire
Merck Announces Third-Quarter 2024 Dividend
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend
Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
Simply Wall St.
Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Merck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could continue, we...